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 Abstract 
Objectives: Friedreich’s ataxia is a devastating neurological disease currently lacking any 
proven treatment. We studied the neuro-protective effects of the cytokines granulocyte-
colony stimulating factor and stem cell factor in a humanised murine model of Friedreich’s 
ataxia. 
Methods: Mice received monthly subcutaneous infusions of cytokines while also being 
assessed at monthly time points using an extensive range of behavioural motor performance 
tests. After 6 months of treatment, neurophysiological evaluation of both sensory and motor 
nerve conduction was performed. Subsequently, mice were sacrificed for mRNA, protein and 
histological analysis of the dorsal root ganglion, spinal cord and cerebellum.   
Results: Cytokine administration resulted in significant reversal of biochemical, 
neuropathological, neurophysiological and behavioural deficits associated with Friedreich’s 
ataxia. Both granulocyte-colony stimulating factor and stem cell factor had pronounced 
effects on frataxin levels (the primary molecular defect in the pathogenesis of the disease), 
and on regulators of frataxin expression. Sustained improvements in motor coordination and 
locomotor activity were seen, even after onset of neurological symptoms. Treatment also 
restored the duration of sensory nerve compound potentials. Improvements in peripheral 
nerve conduction positively correlated with cytokine-induced increases in frataxin 
expression, providing a link between increases in frataxin and neurophysiological function.    
Abrogation of disease-related pathology was also evident, with reductions in 
inflammation/gliosis and increased neural stem cell numbers in areas of tissue injury. 
Interpretation: These experiments show that cytokines already clinically used in other 
conditions offer the prospect of a novel, rapidly translatable, disease-modifying and 
neuroprotective treatment for Friedreich’s ataxia.   
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 Introduction 
Friedreich’s ataxia, the commonest autosomal recessive ataxic condition, is characterised 
neuropathologically by degeneration of large sensory neurons, the spinal cord and the deep 
cerebellar nuclei 
1
. Friedreich’s ataxia patients inevitably acquire neurological disability, with 
progressive ataxia, dysarthria, neuropathy and pyramidal weakness, as well as cardiac and 
endocrine disease 
2
. In most cases, Friedreich’s ataxia is caused by homozygous GAA.TCC 
tri-nucleotide repeat expansion within intron 1 of the FXN gene 
3
 causing transcriptional 
repression of frataxin 
4
. Frataxin is an essential mitochondrial protein, loss of which causes 
disrupted respiratory chain activity, impaired cellular iron homeostasis and oxidative stress, 
leading to cell death in affected tissues 
5-7
. 
 
Currently, there are no treatments that can protect nerves, promote nervous system 
regeneration, or slow disease progression 
8
.  However, specific cytokines and growth factors 
may show therapeutic potential in mediating nervous system injury and repair. Originally 
used clinically for stimulating and mobilising specific sub-sets of bone marrow stem and 
progenitor cell populations prior to a peripheral blood stem cell harvest, the agents 
granulocyte-colony stimulating factor (G-CSF) and stem cell factor (SCF) 
9, 10
, may also 
exhibit direct protective and reparative effects within diseased tissues; and in combination, 
show significant biological and clinical synergy with one another 
11
. Therapeutically, G-CSF 
and SCF are known to cross the blood brain barrier 
12
, exert anti-apoptotic effects on glial 
and/or neural cells 
13, 14
, stimulate neurogenesis and neurite outgrowth 
15, 16
, and promote 
migration of endogenous neural progenitor cells 
17
. Furthermore, these agents promote 
accelerated recovery in several animal models of neurological disease 
18
 and are already in 
human clinical trials for other neurological disorders 
19
. Here, we study the therapeutic 
potential of the repeated subcutaneous administration of both G-CSF and SCF in a humanised 
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 murine Friedreich’s ataxia model. Using recognised cytokine regimens for the mobilisation of 
murine peripheral blood hematopoietic stem cells (HSCs) we demonstrate for the first time 
major benefits in clinical, biochemical, neurophysiological and pathological parameters 
associated with the disease.  
 
 
Methods 
Experimental design 
The objectives of the study were to investigate, in a mouse model of Friedreich’s ataxia 
(YG8R mice), the therapeutic effects of cytokine administration (G-CSF/SCF) on disease 
phenotype.  Experimental protocols are described in Fig 1A. Investigators were blinded to 
treatment group for behavioural studies. 
 
Animals 
All animal experiments were performed in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and approved by the University of Bristol Animal Welfare and Ethical 
Review Body. Fxn
tm1Mkn 
Tg(FXN)YG8Pook/J (YG8R) transgenic mice, which carry a human 
genomic FXN transgene (on a murine frataxin null background) containing expanded GAA 
repeats of 82-190 units within intron 1 of FXN were used. Ataxic (strain# 
Fxn
tm1Mkn
 Tg(FXN)YG8Pook/J, stock # 008398) were purchased from Jackson Laboratory, 
US. Control C57BL/6 VAF/Elite mice were provided by Charles River, UK. All mice were 
housed in a pathogen-free facility, with free access to food and water.  
 
Treatment 
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 Cytokines doses were based on standard regimens for G-CSF mobilisation of peripheral 
blood HSCs. In humans, 5-10 µg kg day of recombinant G-CSF is administered for 4-7 days 
(British National Formulary; BNF 
20
). Mobilising doses of G-CSF for murine HSC is 
considerably higher than for humans to achieve similar levels of mobilisation 
21
, commonly 
100-300 µg kg day is injected for five or more days 
22-24
. The rationale to use cytokines G-
CSF and SCF at a single fixed dosage (200 µg per kg) was to allow comparisons to be made 
between the effectiveness of the two cytokines when used alone.  
Mice received subcutaneous injection of murine G-CSF and/or SCF (Peprotech; both 200 µg 
per kg) in phosphate-buffered saline (PBS) once daily for five consecutive days. Treatments 
were repeated every four weeks. PBS alone was administered as a vehicle control, during the 
same period.  Bromodeoxyuridine (BrdU) (Sigma-Aldrich; 50 mg per kg) in PBS was also 
administered intraperitoneally once daily for five consecutive days (directly following growth 
factor infusion) during the last treatment round.   
 
Peripheral blood mononuclear cell counts 
One hundred microliters of peripheral blood was harvested from the tail vein and suspended 
in PBS pH 7.4/EDTA (2 mg/ml). Red cells were removed using red cell lysis buffer, the 
remaining nucleated cell population re-suspended in PBS/3% foetal bovine serum (FBS) and 
counted using a haemocytometer.  
 
Neurobehavioral testing 
Body Weight 
Mouse body weights were recorded once monthly between 3-9 months of age using a digital 
scale.   
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 Rotarod 
A digital rotarod, rod diameter 30 mm, accelerating from 4 to 40 rpm over 400 s was used. 
(Ugo Basile 47600)  Mice were allowed to stand on the slowly rotating (4 rpm) rod for 30s 
before acceleration. Each month, mice were first trained on the rotarod using three 
unrecorded trials with 15min inter-trial intervals. Six hours later, mice received four recorded 
trials with 15min inter-trial intervals. All trials ended when the mouse fell off the rotarod or 
after a maximum 400s had elapsed. The time that each mouse maintained its balance on the 
rotating rod was measured as the latency to fall. 
 
Grip Strength 
A 2.5 Newton meter was used to assess the forelimb grip strength. Mice were held by the 
base of the tail and allowed to grasp a metal bar attached to the meter. The peak force with 
which mice pulled the bar horizontally was measured in three trials with a rest period of 1 
minute between each trial. 
 
Bar hang test  
Mice were placed with their forepaws grasping the middle of a 200mm horizontal wooden 
bar (4mm thick), secured to a vertical post, elevated 300mm from a flat surface. The ability to 
grip the bar was scored as following: 0 unable to remain on bar; 1  hangs by both forepaws; 2  
attempts to climb onto bar; 3 both forepaws and one or both hind paws around bar; 4  four 
paws and tail around bar, with lateral movement;  5  escape. The score was measured in three 
trials with a rest period of 5 minutes between each trial. 
 
String test  
Page 6 of 42
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
 Mice were placed with their forepaws grasping the middle of a taut 1m horizontal rope (4mm 
thick), suspended between two vertical supports, elevated 300mm from a flat surface. The 
time taken for each mouse to reach either end of the rope was measured. Trials ended when 
the mouse fell off the rope or after a maximum 60s had elapsed. Latency was measured in 
three trials with a rest period of 5 minutes between each trial.  
 
Beam-walk test  
The test was carried out using a wooden beam 900mm long, with an external diameter of 
10mm. Within a darkened room, the beam was placed between two platforms sloping up 
from 300mm to 600mm above the bench surface with lower end mounted on a narrow 
support with a 60W lamp, while a darkened safety platform was located at the other end of 
the beam, in which the mouse could escape. Performance on the beam was quantified by 
measuring the time it took the mouse to traverse the beam and enter the safety platform. The 
latency was measured with a rest period of 5 minutes between each trial. 
 
Open field  
Within a darkened room, mice were placed into a 3 x 3 gridded (300 x 300mm size) clear 
Perspex box with 150mm high walls. A 60W lamp illuminated the arena. The total number of 
grid squares entered, the frequency of central square entered and the total number of hind-
paw rearings by each mouse over a period of 5 minutes was recorded. Scores were measured 
with a rest period of 30 minutes between each trial 
 
Gait analysis 
To obtain footprints, the hind- and forepaws of the mice were coated with red and green 
nontoxic food colouring, respectively. The animals were then allowed to walk along a 
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 500mm long, 55mm wide runway with 100mm high walls (lit at the entrance with a 60W 
lamp), with white paper lining the floor, into a darkened enclosed escape box. All mice 
received both one training and trial run. A fresh sheet of paper was placed on the floor of the 
runway for each run. The footprint patterns of the hind- and forepaws were analysed for four 
step parameters (all measured in millimetres): stride length, stance length, intra-step length 
and overlap distance (shown in Fig 2).  
 
Neurophysiology 
Animals were anaesthetised with ketamine (100mg/kg, Vetalar, Boehringer Ingelheim 
Vetmedica Inc., Missouri USA) and xylazine (10mg/kg, Rompun, Bayer, Berkshirem UK) 
intraperitoneally. The depth of anaesthesia was regularly assessed by a paw pinch to monitor 
reflex muscle tone and supplementary doses were administered as required. Core body 
temperature was maintained at 37°C by a heated blanket.  
 
Tail nerve conduction studies 
Assessment of the conduction velocity of sensory and motor fibres was performed by 
stimulating the distal and proximal parts of the tail respectively, and recording evoked 
responses 
25, 26
. For stimulation of the sensory nerves, two uninsulated needles with a 
separation of approximately 5mm were inserted at the tip of the tail with the cathode. The 
cathode was the most proximal of the needles to the base of the tail. Bipolar recordings were 
made using needle electrodes inserted approximately 20 mm (Position A) and 40 mm 
(Position B) from the cathode. The reference electrode was inserted above the base of the tail. 
For stimulation of motor nerves, the same electrode positions were used except that the 
Page 8 of 42
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
 electrodes in the tip of the tail were used to record the responses and stimulation delivered at 
Positions A and B.  
Electrical stimulation consisted of constant current square pulses of 0.2ms duration delivered 
every 3s. Recordings were made with a stimulus intensity x3 threshold to evoke a response. 
The nerve compound potentials were amplified (x1000), bandpass filtered (5Hz to 5kHz) and 
digitized on-line using a Cambridge Electronic Design (CED, Cambridge, UK) Micro 1401 
analog-to-digital converter and Spike2 software (CED). The latency of the responses was 
taken from stimulus onset time to the beginning of the potential as well as to the peak. The 
distance between the two recording sites was measured with a calliper and the sensory and 
motor nerve conductions calculated by dividing the distance by the difference in latencies of 
the proximal and distal recording sites. For each animal analysis of sensory and motor 
conduction velocities and nerve volley duration was based on an average of 10 trials. 
 
Tissue processing 
Mice were sacrificed and tissues for both proteomic and genomic analyses were dissected, 
immediately snap-frozen in liquid nitrogen and stored at -80ºC until use. Frozen tissue was 
then thawed and homogenized on ice by use of the PARIS kit (Ambion, UK) and a protease 
and phosphatase inhibitor cocktail (1:100; Thermo Scientific, UK).  
For histological analyses, mice were anaesthetised by intraperitoneal injection of Euthatal and 
perfused with PBS followed by 4% paraformaldehyde in PBS. The brains and spinal cords 
were dissected and placed in 4% paraformaldehyde in PBS for 24h at 4°C and subsequently 
embedded in paraffin for sectioning on a rotary microtome (Leica LM2135) and mounting on 
glass slides. 
 
Gene expression analysis: Quantitative PCR 
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 Total RNA was extracted from tissue lysates on ice using the PARIS kit (Ambion, UK) 
according to manufacturer’s instructions and treated with DNase I recombinant 
(Roche)/MgCl2 solution (Quantace).  All RNA samples were quantified using a Qubit 
Fluorometer and Quant-iT RNA assay kit (Invitrogen, Paisley, UK) according to 
manufacturers’ instructions. RNA was reverse transcribed to produce cDNA using the High 
Capacity cDNA Kit (Applied Biosystems, Foster City, CA, USA) and qPCR performed using 
TaqMan Fast Advanced Master Mix (Applied Biosciences) and StepOnePlus™ Real-Time 
PCR System (Applied Biosystems, UK) with primers for Epas1  (Mm01236112_m1), FXN 
(Hs00175940_m1),  Srf (Mm00491032_m1), Tfap2a (Mm00495574_m1); Trp53 
(Mm01731290_g1) (TaqMan MGB probe, FAM dye-labelled, Applied Biosystems, Paisley, 
UK). The relative gene expression (RQ value) was calculated using the 2
-∆∆Ct 
method with 
both Beta Actin (Actb; Mm00607939_s1) and NeuN (Rbfox3; Mm01248771_m1) used as 
housekeeping genes. 
 
Protein analysis 
The Qubit ® Fluorometer and Quant-iT™ protein assay kit (Invitrogen, UK) was used to 
quantify the concentration of total protein within each tissue homogenate. Frataxin levels 
were measured using the Frataxin Human SimpleStep ELISA kit (Abcam) and the enzyme 
activity of Aconitase was determined using the Aconitase assay kit (Caymen Chemical).  
For further quantitative protein analysis, immuno dot-blotting was carried out using the Bio-
Dot Microfiltration manifold system (Biorad). Protein homogenates were transferred to the 
nitrocellulose membrane using gravity filtration, blocked using 5% BSA, before incubation 
with the following primary antibodies:- Catalase (Abcam; ab16731 1:5000), GPX1 (Abcam; 
ab22604 1:5000), 4-HNE (Abcam; ab48506 1:6000), Nrf2 (Santa Cruz; sc-722 1:2000), 
PGC-1a (Santa Cruz; sc-13067 1:2000), NeuN (Abcam; ab177487 1:4000), SOD1 (Abcam; 
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 ab16831 1:5000),  SOD2 (Abcam; ab16956 1:20000). Immunoreactivity was detected using 
HRP-conjugated goat anti-mouse IgG (1:5000; Ab6789) or anti-rabbit IgG (1:3000; Ab6721) 
secondary antibodies (Abcam).  Protein expression was visualised using a 
chemiluminescence EZ-ECL kit in conjunction with a Biorad Universal III Bioplex imager.  
Densitometric analysis of protein expression was performed using Image Lab™ 5.0 software 
(Biorad).   
 
Immunohistochemistry and imaging 
Mounted tissue sections were deparaffinised, hydrated and washed with PBS. For antigen-
exposing pre-treatment, sections were incubated with boiling 0.01M Sodium Citrate buffer 
pH 6.0. Immunohistochemical staining with DAB has been described previously 
27
. For 
immunofluorescent labelling, non-specific binding was blocked with 10% normal goat serum 
diluted in PBS containing 0.1% triton. Sections were incubated at 4°C overnight with primary 
antibodies to 4-HNE (Abcam; ab48506 1:200), Beta-3 tubulin (Abcam; ab78078 1:250), 
BrdU (Sigma-Aldrich; B2531), Calbindin-D28K (Sigma-Aldrich; C2724 1:500), GAD 
(Abcam; ab11070 1:1000), GFAP (Abcam; ab33922 1:200), MBP (Serotec; MCA4095 
1:100), NeuN (abcam; ab177487 1:500 & ab104224 1:500), Nestin (BD bioscience; 556309 
1:200), OX42 (Abcam; ab1211 1:100), S100 (Milipore; MAB079 1:200), S100 (Dako; Z0311 
1:200). Sections were washed in PBS and incubated for 45 minutes in the dark with Alexa 
Fluor 488/555, goat anti-mouse (1:500) or Alexa Fluor 488/555, goat anti-rabbit (1:500) 
(Invitrogen, Paisley, UK), before being mounted in Vectashield medium containing the 
nuclear dye 4′6′-diamidino-2-phenylindole (DAPI) (H-1200, Vector Laboratories). For BrdU 
labelling, sections were incubated at 37°C in 2N HCl for 30 mins followed by 0.1% Trypsin 
for 20 mins prior to blocking.  
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 Confocal analysis was performed using either a Leica SP5-AOBS confocal laser scanning 
microscope attached to a Leica DM I6000 inverted epifluorescence microscope; or a Nikon 
C1 confocal microscope and EZ viewer software. All Z-stack and 3-dimensional imaging was 
created using both Leica Application Suite Advanced Fluorescence software and Volocity 3D 
image software (PerkinElmer, USA). For light imaging, images were acquired using an 
Olympus IX70 microscope coupled with Image-Pro Plus software. 
 
Histological staining  
For histological assessment, tissues were sectioned, deparaffinated, hydrated, and stained 
with hematoxylin and eosin (H&E) (visualisation of dorsal root ganglion (DRG) vacuoles) or 
Luxol fast blue/cresyl violet (visualisation of myelin).  
 
Cell quantification 
At least four independent tissue samples from each group were included in the analyses. All 
cells were counted within randomly assigned set areas within the DRG, spinal cord and 
dentate nucleus. For spinal cord sections, representative samples of cervical, thoracic and 
lumbar were all analysed.  
 
DRG Vacuoles 
Each section was scanned across the entire cross-sectional area of the DRG for neuronal cell 
bodies containing either nuclear and/or cytoplasmic vacuoles. A minimum of 400 DRG 
neurons from each mouse was examined, allowing for the determination of the frequency of 
vacuolated cells. 
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 Neuronal cell size 
To quantify changes in neuronal size, the cross-sectional diameter of a nucleated cell soma 
was measured in each cell using ImageJ software. Neurons were identified by either Beta-3 
tubulin (dentate nucleus) or NeuN/H&E (DRG).  
 
Statistical analysis 
The analysis was performed using GraphPad Prism (GraphPad Software Inc, USA). For all 
tests, values of p<0.05 were considered statistically significant. Statistical tests were all two-
sided. At least 5 independent tissue samples or mice from each group were included in the 
analyses. Data between two groups were analysed using either unpaired t-tests or Mann-
Whitney U tests. Statistical comparisons for over two groups were analysed using either 
Friedman test, one-way or two-way analysis of variance (ANOVA) with post hoc testing 
between groups where appropriate (as indicated in figure legends). Where possible, data are 
represented as mean ± SEM, or for qPCR data geometric mean ± 95% confidence intervals 
are stated.   
 
 
Results  
To investigate G-CSF/SCF administration, we used three month Fxn
tm1Mkn 
Tg(FXN)YG8Pook/J (YG8R) transgenic mice, which carry human genomic FXN transgene 
(on a murine frataxin null background) containing a GAA expansion within intron 1. Mice 
are frataxin-deficient and develop progressive neurodegeneration and cardiac pathology 
28, 29
. 
Due to the phenotypic similarity between C57BL/6 and Y47R (containing the human FXN 
transgene with normal-sized GAA repeats) mice, C57BL/6 mice were used as healthy 
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 controls 29.  Before any therapeutic intervention, neurological deficits were already apparent 
in the YG8R mice compared to age-matched wild-type controls. These deficits in the YG8R 
mice became more prominent with increasing age (Fig 1C to H, Fig 2).  
 
 (a) G-CSF and SCF improve both motor and locomotor performance in YG8R mice 
YG8R transgenic mice were subcutaneously injected with PBS (controls) or G-CSF and/or 
SCF dissolved in PBS (daily for five consecutive days) monthly for six consecutive months 
(Fig 1A). For the duration of the study, no observable side effects in the mice were noted post 
G-CSF and/or SCF administration, weights remained consistent/normal (Fig 3B)  and all 
mice (n = 50) completed the study. Combined G-CSF/SCF increased peripheral blood MNC 
counts approximately 8-fold, and was a more effective mobilising regimen compared to 
administration of single agents (Fig 3A).     
Motor coordination and locomotor activity in YG8R and Control mice was assessed monthly.  
Significantly, after six months of G-CSF and/or SCF administration, improvements were seen 
in the majority of motor coordination and locomotor activities tested (Fig 3C to I). 
Performances were independent of changes in body mass (Fig 3B). 
 
(b) G-CSF and SCF increase frataxin mRNA and protein expression  
Transcriptional repression of FXN is the primary molecular event in the pathogenesis of 
Friedreich’s ataxia 
3, 4
. To explore potential neuroprotective mechanisms of G-CSF and SCF, 
we measured frataxin mRNA levels in cerebellum and spinal cord of YG8R mice (aged 9 
months) 24 hours post-injection of cytokines. FXN mRNA levels were significantly amplified 
following treatment, with G-CSF or G-CSF/SCF (cerebellum) and G-CSF/SCF (spinal cord) 
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 having the most pronounced effects (Fig 4B). Notably, in all cases increases in frataxin 
mRNA expression were more prominent using the neuronal specific marker NeuN 
housekeeping gene comparator, suggesting that the treatments, at least in part, potentiate 
increases in neuronal frataxin.  
 
Transcriptional repression of FXN is thought to result from reduced accessibility of 
transcriptional regulatory factors to the promoter region caused by the tri-nucleotide repeat 
expansion 
30
, and various regulatory factors binding close to the FXN gene locus are 
implicated 
31-33
 (Fig 4A). Of these, we found that Tumour Protein p53 (p53; encoded by 
Trp53), Transcription Factor AP-2 alpha (TFAP2A; encoded by Tfap2a), Serum Response 
Factor (SRF; encoded by Srf) and Hypoxia-Inducible Factor-2alpha (HIF-2A; encoded by 
Epas1) were increased following cytokine administration (Fig 4C). Of the regulatory factors 
tested, only Epas1 and Trp53 were upregulated in both cerebellum and spinal cord in 
response to cytokine administration; and of these only Epas1 expression in treated mice 
correlated with respective FXN expression Fig 4D.   
 
We also showed marked increases in frataxin protein expression within the spinal cord, and 
to a lesser extent in the cerebellum, with G-CSF or G-CSF/SCF administration (using a 
human-specific frataxin ELISA, as with qPCR analysis,  did not allow comparisons between 
the ‘human’ frataxin levels within YG8R mice and control mouse frataxin levels; Fig 4B).  
 
Frataxin deficiency results in increased oxidative stress and impaired recruitment of 
antioxidant defences 
34
. YG8R mice have reduced protein levels of Peroxisome proliferator-
Activated Receptor gamma coactivator 1-alpha (PGC-1a) and Nuclear Factor (erythroid-
derived 2)-like 2 (Nrf2) in either the spinal cord and/or cerebellum 
35, 36
. This was associated 
Page 15 of 42
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
 with global reductions in expression of anti-oxidant enzymes and enzymatic activity of the 
iron-sulphur protein aconitase within the cerebellum 
28
 (Table 1). Untreated YG8R mice 
showed increases in the lipid peroxidation product 4-HNE, within cerebellum and spinal cord 
(Table 1).   
 
Administration of cytokines led to restoration of aconitase activity in cerebellum and spinal 
cord to, or beyond, levels seen in wild-type control mice.  Similarly, there were increases in 
levels of PGC-1a and Nrf2 protein expression with associated elevations in superoxide 
dismutase 1 and 2 (SOD1 and SOD2), catalase and glutathione peroxidase. Finally, consistent 
with cytokines facilitating redox homeostasis, in cerebellum and spinal cord, reductions in 4-
HNE were also apparent with combined administration of G-CSF and SCF (Table 1).   
 
(c) G-CSF and SCF improve nerve conduction 
Since Friedreich’s ataxia patients exhibit abnormalities in nerve conduction 
37
, 
neurophysiological evaluation of sensory and motor nerve conduction was performed. 
Electrophysiological recordings were obtained from the tail nerves of wild-type controls, 
untreated YG8R mice and YG8R mice treated with combined G-CSF/SCF (Fig 5A to D). 
There was no statistical difference in the sensory or motor conduction velocities among all 
three groups regardless of whether the peak (Fig 5C) or onset latency was used. However, the 
duration of the sensory compound nerve potential in untreated YG8R mice was significantly 
longer than that of wild-type controls, signifying temporal dispersion of the nerve impulses 
evoked by the stimulation. Furthermore, G-CSF/SCF treatment restored nerve volley duration 
to normal levels (Fig 5C).  
Electrophysiological abnormalities in Friedreich’s ataxia correlate with GAA triplet repeat 
expansion length 
38
 (and therefore reduced frataxin protein expression). We found that 
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 increases in cerebellar frataxin protein levels in G-CSF/SCF treated mice significantly 
correlated with shorter duration and increased conduction velocity of sensory compound 
nerve potentials (Fig 5D). These findings provide support for a link between increases in 
frataxin and neurophysiological improvements observed in treated YG8R mice. 
 
(d)  G-CSF and SCF reduce DRG, spinal cord and cerebellar Friedreich’s ataxia-
related pathology 
We further characterised neuropathological changes in YG8R mice.  In common with human 
Friedreich’s ataxia 
1
 and previous studies describing the YG8R mouse 
28, 39
, untreated YG8R 
mice displayed: frequent intra-nuclear and intra-cytoplasmic vacuolisation of the large 
sensory neuronal cell bodies of the dorsal root ganglia (DRG) with significant lipofuscin 
accumulation (Fig 6A to D) and an increased satellite cell to DRG neuron ratio (Fig 6E) 
representing large sensory DRG neuronal loss (Fig 6F to G) and/or subsequent satellite cell 
proliferation; neuronal loss in the spinal cord dorsal nucleus of Clarke (DNoC) (Fig 6H to I); 
atrophy of large neurons within the cerebellar dentate nucleus with grumose-type glutamic 
acid decarboxylase (GAD) positive intracytoplasmic labelling pattern in the large neuronal 
cell bodies of the YG8R  (Fig 6J to M); spinal cord astrocytosis associated 4-
Hydroxynonenal (4-HNE) accumulation at the peripheral aspects of the anterior and lateral 
white matter tracts and extending into the dorsal columns (Fig 7C, D, G), although no 
significant white matter loss (Fig 7E to F). Patchy astrocytosis was also seen in the grey 
matter surrounding the central canal and extending towards the DNoC (Fig 7G); influx of 
inflammatory OX42 (CD11b/c) positive cells in both the spinal cord and dentate nucleus (Fig 
7A to B); and reduction in nestin-positive cells in lateral corticospinal tracts, DNoC and 
dentate nucleus, compared to wild-type control mice (Fig 7H to I). 
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 We observed clear attenuation of Friedreich’s ataxia-associated pathology within the DRG, 
spinal cord and cerebellum of YG8R mice treated with cytokines. All treatment regimens led 
to significant reductions in the number of DRG neurons containing either intra-cytoplasmic 
or intra-nuclear vacuoles (Fig 6A to C). Furthermore, treatment returned satellite-cell-to-
neuronal ratios to levels found in wild-type controls - a likely consequence of improved large 
sensory neuronal cell survival (Fig 6E to G). Combined G-CSF/SCF treatment markedly 
reduced neuronal loss within the spinal cord DNoC (Fig 6H to I); and reduced the extent of 
astrocytosis and inflammatory cell infiltrate within dorsal columns, spinocerebellar and 
corticospinal tracts (Fig 7A to D). In the dentate nucleus, both G-CSF and SCF reduced 
atrophy of large neurons (resulting in an increased mean neuronal cell size) and reduced the 
presence of grumose degeneration (Fig 6J to M).   
 
To assess the effects of treatment on cellular kinetics, YG8R mice were injected with the 
thymidine analogue 5-bromo-2'-deoxyuridine (BrdU) directly following cytokine treatment 
during the final treatment round (Fig 1A). Histological analysis one month post-BrdU 
revealed a distinct reduction in BrdU cell numbers within DRG  of untreated YG8R mice 
(compared to wild-type controls) but marked increases in BrdU cells in DRG, dorsal spinal 
roots, dentate nucleus, and to a lesser extent in the spinal cord in G-CSF and/or SCF-treated 
mice (Fig 7J). We also found the pool of nestin-positive neural precursor cells within the 
DRG, spinal cord and dentate nucleus was significantly amplified in response to treatment 
with G-CSF and/or SCF (Fig 7H to I).  
 
 
Discussion 
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 Here we show that administration of G-CSF and SCF have marked direct neuroprotective 
effects in a ‘humanised’ mouse model of Friedreich’s ataxia; these agents correct many 
Friedreich’s ataxia-associated biochemical abnormalities and improve functional, 
neurophysiological and pathological parameters. Significantly, administration of G-CSF 
and/or SCF mediates sustained improvements in motor coordination and locomotor activity 
in YG8R ‘Friedreich’s’ mice, even after onset of clinical symptoms. Treatment also restored 
the duration of sensory nerve compound potentials, reflecting reduced variability in 
conduction velocities of individual nerve fibres associated with Friedreich’s ataxia 
dysfunction 
37, 38
.  
 
G-CSF and SCF had pronounced effects on frataxin levels, and on regulators of frataxin 
expression within both the cerebellum and spinal cord. Of the potential transcription factors 
we tested 
31-33
, HIF-2alpha encoded by Epas1 was upregulated in the cerebellum and spinal 
cord in response to treatment and correlated with FXN expression, highlighting a possible 
regulatory mechanism by which G-CSF and SCF control frataxin expression. Indeed, others 
have shown that HIF-2alpha can activate the murine FXN promoter through binding to a 
consensus HIF-responsive enhancer element (HRE), and mice lacking Epas1 have markedly 
reduced levels of frataxin 
33
.  
 
Interventions that increase the amount of the frataxin protein are attractive therapeutic 
approaches. Carriers of the GAA expansion, having approximately 50% of normal frataxin 
expression, are asymptomatic 
5, 40
. Increasing cellular frataxin levels above a specific 
threshold therefore hold promise; a recent proof-of-concept study introducing FXN 
transgenes into heart cells of frataxin-deficient mice led to overexpression of frataxin and 
sustained remission of Friedreich’s ataxia-associated heart disease 
41
. Experimentally several 
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 agents have shown potential to increase frataxin expression (recombinant erythropoietin, 
interferon-gamma, nicotinamide and resveratrol), however there has been limited success in 
their capacity to elevate frataxin levels when tested clinically 
42-45
.   
 
Molecules coupled with frataxin deficiency were also elevated in response to treatment. 
Specifically, G-CSF and/or SCF increased expression of molecules associated with frataxin 
antioxidant functions including Nrf2, superoxide dismutases, catalase and glutathione 
peroxidase. Nrf2 is a key orchestrator of cellular anti-oxidant responses and its 
expression/activity is reduced in frataxin-deficient cells leading to increased oxidative injury 
35, 46, 47
. Cytokines also increased expression of PGC-1a, another key regulator of cellular 
redox homeostasis 48, and reduced lipid peroxidation products 49, thus confirming their anti-
oxidative effects.  
 
YG8R mice replicate human disease in many histological aspects, with neuronal atrophy in 
the DRG, DNoC and dentate nucleus. Importantly, repeated administration of cytokines led 
to significant amelioration in disease-related pathology throughout the nervous system, the 
likely explanation for the observed improvements in motor and locomotor function. 
Mechanistically, in addition to restoring frataxin-associated cellular homeostasis, G-CSF/SCF 
attenuating inflammation (both astro- and microgliosis) in the nervous system of YG8R mice 
may have also slowed the progression of the disease 
50
.  
 
Adult neurogenesis appears to be an important mechanism of brain plasticity in brain repair 
after injury 
51
. We found reduced numbers of proliferating cells and neural precursors 
throughout the nervous system of untreated YG8R mice.  This may be a consequence of 
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 mitochondrial dysfunction induced by frataxin deficiency 
52
 and abnormal neurogenesis may, 
in turn, exacerbate neuropathology 
53
. Both G-CSF and SCF regulate proliferation, 
differentiation and recruitment of endogenous neural and BM progenitor cells during 
neurological injury 
17, 54
. In accordance, cytokine administration increased the number of both 
nestin-positive and proliferating cells in the YG8R nervous system. Of note, numbers of 
nestin cells were elevated in the DRG, DNoC and dentate nucleus, all areas in which 
neuronal preservation was apparent in response to treatment.  
 
As demonstrated here, humanised mice are powerful tools in pre-clinical testing of potential 
therapeutic agents of neurological disease; however, care should be taken when interpreting 
data due to underlying genomic differences between rodents and humans. We believe these 
observations warrant further clinical trials of stem cell mobilising agents in patients with 
Friedreich’s ataxia. When used clinically, both G-CSF and SCF are generally well tolerated 
with G-CSF having a well-established safety record in healthy peripheral blood stem cell 
donors. The pharmacokinetics of G-CSF administration has been extensively studied in 
humans and the therapeutic window, in terms of achieving HSC mobilisation, can extend 
beyond twice the recommend dose 
55
. Furthermore, monthly administrations of mobilising 
agents have been shown to be safe in a trial for amyotrophic lateral sclerosis 
19
. This has 
provided early safety data on the use of G-CSF for neurodegenerative conditions.  
 
In conclusion, these experiments have elucidated mechanisms of action of cytokines in a 
‘humanised’ Friedreich’s ataxia mouse model. Their pleiotropic effects contribute to 
neuroprotection and repair against Friedreich’s ataxia-associated pathological mechanisms, 
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 thereby offering a therapy that may reduce or even help reverse long-term disability in 
patients with Friedreich’s ataxia.  
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Figure legends. 
Fig 1. Neurological deficits in YG8R mice that carry a human genomic FXN transgene 
containing expanded GAA repeats of 82-190 units within intron 1 of the frataxin gene.  (A) 
Experimental protocol using wild-type controls (WT) and YG8R mice to investigate the 
effects of cytokine administration on disease phenotype. Mice received monthly infusions of 
cytokines (red arrows) while also being assessed at monthly time points using an extensive 
range of behavioural performance tests. Bromodeoxyuridine (BrdU) was also administered 
during the last round of growth factor treatment (blue arrow).  At 9 months of age 
neurophysiological evaluation of both sensory and motor nerve conduction was performed. 
Subsequently, mice were sacrificed for mRNA, protein and histological analysis.  
Comparisons between WT-control and untreated YG8R mice:- longitudinal results for (B) 
weight; (C-G) motor performance; and (H) locomotor performance (open field test), in mice 
from 3 to 9 months of age.  Repeated measures (RM) two-way ANOVA was applied for all 
behavioural studies. ns (not significant), *P < 0.05,**P < 0.01, ***P < 0.001, values 
represent means ± SEM. For all tests, n = 10 (5 female and 5 male) per genotype. 
 
Fig 2. YG8R mice show gait abnormalities. Comparisons between WT-control and untreated 
YG8R mice:- (A) footprint (gait) analysis and (B) representative footprint traces in mice 9 
months of age.  The unpaired t-test was applied for all analysis. *P < 0.05,**P < 
0.01, ***P < 0.001, values represent means ± SEM. For all tests, n = 10 (5 female and 5 
male) per genotype. 
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Fig 3. Treatment with G-CSF and/or SCF improves both motor and locomotor 
performance in YG8R mice. (A) The peripheral blood MNC counts of WT control and 
YG8R mice subcutaneously injected with G-CSF and/or SCF dissolved in PBS (200µg/kg 
body weight daily for 5 consecutive days). Longitudinal results for (B) weight; (C-G) motor 
performance; (H) locomotor performance (open field test); and (I) gait analysis, in YG8R 
mice treated with G-CSF and/or SCF, from 3 to 9 months of age. All statistical comparisons 
are vs YG8R mice using either the unpaired t-test, one-way or RM two-way ANOVA 
followed by Dunnett’s multiple comparison test.  ns (not significant), *P < 0.05, **P < 
0.01, ***P < 0.001, values represent means ± SEM. For all neurobehavioral tests, n = 10 (5 
female and 5 male) per genotype.  
 
Fig 4. Both frataxin and regulatory factors implicated in controlling frataxin transcription 
are elevated in the cerebellum and spinal cord of YG8R mice treated with G-CSF and/or 
SCF. (A) A schematic of the 5’ end of the frataxin (FXN) gene showing the locations of the 
binding sites (yellow bars) for HIF-2A, SRF, TFAP2A and p53.  The locations of the 
promotor (PR), Exon1, Exon2 and Intron1 regions are depicted. Different transcription start 
sites (TTS1 and TSS2) are shown upstream of Exon1, which holds the ATG translation start 
site. The directions of transcription for FXN (red arrows) and FXN anti-sense transcript 
(FAST-1; dashed black arrow) are shown. The red triangle indicates the site of the 
trinucleotide GAA repeat expansion within intron 1 of FXN gene of patients with FRDA.  
The relative (B) mRNA and protein expression levels of frataxin within the cerebellum and 
spinal cord of YG8R mice (normalised to NeuN or β actin); (C) mRNA expression levels of 
transcription factors implicated in controlling frataxin expression Epas1, Srf, Tfap2a and 
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 Trp53 (normalised to NeuN). (D) The correlation and linear regression analysis of FXN and 
Epas1 mRNA levels (normalised to NeuN) in the spinal cord and cerebellum of treated 
YG8R mice (lines of best fit and 95% CI are depicted), r = Spearman’s correlation 
coefficient.  All statistical comparisons are vs YG8R mice. Comparisons between control and 
untreated YG8R mice were analysed using unpaired t-tests or Mann-Whitney U tests. For all 
other analyses, either one-way ANOVA followed by Dunnett’s multiple comparison test or 
Kruskal-Wallis followed by Dunn’s multiple comparison test was applied for all 
analyses. *P < 0.05, **P < 0.01, ***P < 0.001. For mRNA and protein expression, values 
represent the geometric means ± 95% CI and means ± SEM respectively. For all tests, n = 4 
or 5 per genotype.   
 
Fig 5. Neurophysiological deficits of the sensory nerve pathway are restored in YG8R mice 
treated with a combination of G-CSF and SCF. (A) Sensory compound nerve recording 
from the proximal tail after stimulation at the tail tip. (B) Motor compound nerve recording 
from the distal tail after stimulation of the proximal tail. The first small negative wave is due 
to antidromic activation of sensory fibres. (A) and (B) Responses are an average of 10 trials 
and from control animals. Arrowhead indicates the onset of the electrical stimulation. (C) 
Peak conduction velocities and durations of sensory and motor responses recorded from tails 
of wild type controls, untreated YG8R mice and YG8R mice treated with combined G-
CSF/SCF. (D) The correlation and linear regression analysis of frataxin protein levels 
(normalised to NeuN) in the spinal cord and cerebellum of treated YG8R mice with either 
sensory nerve conduction velocity or wave duration (lines of best fit and 95% CI are 
depicted). All statistical comparisons are vs YG8R mice. One-way ANOVA followed by 
Dunnett’s multiple comparison test was applied for all analyses. *P < 0.05, values represent 
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 means ± SEM. Spearman’s correlation was used to analyse relationships between frataxin 
and sensory nerve conduction velocity or wave duration. r = correlation coefficient.   
 
Fig 6. G-CSF and SCF administration improves Friedreich’s ataxia-associated pathology. 
(A) Haematoxylin and eosin-stained DRG depicting reductions in vacuolisation (red arrows) 
of large sensory neurons within YG8R mice treated with G-CSF/SCF. (B) High powered 
image of a DRG neuron showing significant vacuolisation (red arrow). (C) The frequency of 
DRG neurons containing vacuoles. (D) DRG sections labelled with NeuN and S100 showing 
auto-fluorescent lipofuscin (black arrow) and both intra-nuclear (white asterisk) and intra-
cytoplasmic (white arrow) vacuolisation. (E) The DRG satellite-to-neuron cell ratio; (F) the 
size range and (G) mean cell size (diameter) of DRG neurons. (H) Images and (I) numbers of 
NeuN-labelled neurons within the DNoC of YG8R mice treated with G-CSF/SCF. (J) Images 
of Beta-3 tubulin-expressing neurons and (K) grumose-type GAD-positive intracytoplasmic 
labelling pattern in and around the large neuronal cell bodies within the dentate nucleus of 
control and YG8R mice.  (L) The size range, (M) mean cell size (diameter) of Beta-3 tubulin-
labelled neurons within the dentate nucleus. Comparisons between WT-control and YG8R 
mice were compared using the unpaired t-test. All other statistical comparisons are vs YG8R 
mice using either one-way ANOVA followed by Dunnett’s multiple comparison test or 
Kruskal-Wallis followed by Dunn’s multiple comparison test. *P < 0.05, **P < 0.01, ***P < 
0.001, values represent means ± SEM. For all tests, n = 5 per genotype.   
 
Fig 7. G-CSF and SCF administration reduces glial/immune cell infiltration while 
stimulating the recruitment of neural precursors to areas of tissue injury. Numbers of (A) 
OX42- and (C) GFAP-positive cells within the spinal cord and dentate nucleus. (B) 
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 Cerebellar sections depicting levels of OX42-positive cells in the dentate nucleus. (D) Spinal 
cord sections depicting levels of GFAP-positive cells within the spinal cord anterior 
corticospinal tract. Astrocytosis without loss of spinal cord white matter in YG8R mice 
observed using (E) luxol fast blue/cresyl violet staining and (F) MBP-dual immunolabelling 
with GFAP. (G) Spinal cord sections immunolabelled with GFAP and either MBP or 4-HNE, 
exhibiting astrocytosis, in both the white and grey matter, associated with 4-HNE 
accumulation.  (H) Nestin cells/mm
2 
and (I) images of nestin-positive cells within DRG, 
spinal cord and dentate nucleus. (J) BrdU cells/mm
2 
within DRG, spinal cord and dentate 
nucleus. Dorsal column (DC), spinocerebellar tract (SCT), lateral corticospinal tract (LCST), 
anterior corticospinal tract (ACST), dentate nucleus of Clarke (DNoC). Comparisons between 
WT-control and YG8R mice were compared using the unpaired t-test. All other statistical 
comparisons are vs YG8R mice using either one-way ANOVA followed by Dunnett’s 
multiple comparison test or Kruskal-Wallis followed by Dunn’s multiple comparison test. 
*P < 0.05, **P < 0.01, ***P < 0.001, values represent means ± SEM. For all tests, n = 5 per 
genotype.   
 
 
Tables.  
Table 1. Friedreich’s ataxia associated molecules and anti-oxidant defences are restored 
in both the cerebellum and spinal cord of YG8R mice treated with G-CSF and/or SCF. The 
relative protein expression levels of frataxin; aconitase enzyme activity; transcription factors 
Nrf2 and PGC1A; anti-oxidant enzymes SOD1, SOD2, catalase and GPX1, and lipid 
peroxidation product 4-HNE, within the cerebellum and spinal cord of both WT controls and 
YG8R mice and YG8R mice treated with G-CSF and/or SCF. All statistical comparisons are 
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 vs YG8R mice. Comparisons between control and untreated YG8R mice were analysed using 
unpaired t-tests or Mann-Whitney U tests. For all other analyses, either one-way ANOVA 
followed by Dunnett’s multiple comparison test or Kruskal-Wallis followed by Dunn’s 
multiple comparison test was applied for all analyses. *P < 0.05, **P < 0.01, ***P < 0.001. 
Values represent the mean ± SEM, relative to values in untreated YG8R mice. For all 
tests, n = 5 per genotype.   
 
Protein Site Level relative to Control YG8R YG8R +   
G-CSF 
YG8R + 
SCF 
YG8R  + 
SCF/G-CSF 
Friedreich’s ataxia associated molecules 
Nrf2 cerebellum total protein 1.40 (0.08)** 1.00 (0.05) 1.12 (0.09) 1.40 (0.18)* 1.45 (0.10)* 
 
NeuN 1.27 (0.02)* 1.00 (0.09) 1.66 
(0.17)** 
1.54 (0.13)* 1.50 (0.11)* 
spinal cord total protein 0.95 (0.05) 1.00 (0.07) 0.85 (0.10) 1.19 (0.11) 1.08 (0.11) 
 
NeuN 1.61 (0.26) 1.00 (0.16) 2.06 (0.26)* 1.88 (0.33) 2.06 (0.16)* 
 
PGC-1a cerebellum total protein 1.45 
(0.08)*** 
1.00 (0.04) 1.23 (0.10) 1.31 (0.10) 1.38 (0.09)* 
NeuN 1.30 (0.02)* 1.00 (0.08) 1.81 
(0.18)** 
1.45 (0.13) 1.43 (0.14) 
spinal cord total protein 1.18 (0.04)* 1.00 (0.06) 1.06 (0.07) 1.38 
(0.09)** 
1.20 (0.08) 
NeuN 1.96 (0.40)* 1.00 (0.20) 2.46 
(0.25)** 
2.09 (0.30)* 2.26 
(0.26)** 
Aconitase  
 
cerebellum total protein 1.76 
(0.12)*** 
1.00 (0.06) 1.22 (0.16) 1.11 (0.10) 1.61 
(0.10)** 
NeuN 1.54 (0.16)** 1.00 (0.07) 1.72 
(0.02)** 
1.24 (0.11) 1.70 
(0.12)** 
spinal cord total protein 1.03 (0.11) 1.00 (0.10) 1.79 (0.38) 0.94 (0.20) 1.83 (0.14) 
 
NeuN 1.70 (0.35) 1.00 (0.27) 4.07 
(0.87)** 
1.29 (0.23) 3.36 (0.34)* 
Anti-oxidant enzyme/oxidative damage expression 
SOD1 cerebellum total protein 1.37 (0.05)** 1.00 (0.05) 1.17 (0.08) 1.28 (0.07)* 1.22 (0.08) 
 
NeuN 1.22 (0.03)* 1.00 (0.06) 1.74 
(0.15)** 
1.44 (0.15) 1.27 (0.10) 
spinal cord total protein 1.42 (0.11)* 1.00 (0.06) 1.01 (0.11) 1.54 
(0.06)** 
1.40 (0.18) 
NeuN 2.28 (0.31)** 1.00 (0.20) 2.30 
(0.18)** 
2.32 
(0.31)** 
2.60 
(0.34)** 
SOD2 cerebellum total protein 1.30 (0.12) 1.00 (0.08) 1.34 (0.07) 1.72 
(0.13)*** 
1.32 (0.14) 
NeuN 1.19 (0.11) 1.00 (0.07) 2.01 
(0.22)** 
1.97 
(0.28)** 
1.37 (0.13) 
spinal cord total protein 1.39 (0.24) 1.00 (0.05) 2.21 
(0.14)*** 
2.76 
(0.26)*** 
1.79 (0.20)* 
NeuN 2.07 (0.25) 1.00 (0.23) 4.94 
(0.43)** 
3.96 (0.46)* 3.67 (1.16)* 
Catalase cerebellum total protein 1.57 (0.13)** 1.00 (0.05) 1.23 (0.06) 1.42 
(0.06)** 
1.31 (0.12)* 
NeuN 1.45 (0.08)** 1.00 (0.05) 1.84 
(0.19)** 
1.63 (0.21)* 1.35 (0.10) 
spinal cord total protein 1.40 (0.19)* 1.00 (0.06) 1.75 
(0.12)*** 
2.04 
(0.13)*** 
1.62 
(0.12)** 
Page 34 of 42
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
 NeuN 1.84 (0.06)* 1.00 (0.23) 3.96 
(0.47)*** 
2.95 (0.37)* 3.09 (0.64)* 
GPX1 cerebellum total protein 1.30 (0.08)* 1.00 (0.07) 1.21 (0.11) 1.40 (0.05)* 1.39 (0.12)* 
 
NeuN 1.51 (0.32) 1.00 (0.06) 1.78 
(0.10)*** 
1.59 
(0.12)*** 
1.44 (0.08)* 
spinal cord total protein 0.93 (0.05) 1.00 (0.10) 0.91 (0.03) 1.25 (0.04) 1.30 (0.15) 
 
NeuN 1.69 (0.29) 1.00 (0.13) 2.29 
(0.25)** 
2.02 (0.23)* 2.06 (0.26)* 
4-HNE cerebellum total protein 0.55 (0.02)* 1.00 (0.13) 0.74 (0.06) 0.95 (0.02) 0.67 (0.09)* 
 
NeuN n/a n/a n/a n/a n/a 
 
spinal cord total protein 0.54 (0.08)* 1.00 (0.11) 0.88 (0.10) 0.85 (0.12) 0.67 (0.06) 
 
NeuN n/a n/a n/a n/a n/a 
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